Bibliography
- Ebert MP , ModelF, MooneySet al. : Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas.Gastroenterology131, 1418–1430 (2006).
- deVos T , TetznerR, ModelFet al. : Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer.Clin. Chem.55, 1337–1346 (2009).
- Jass JR : Colorectal cancer: a multipathway disease.Crit. Rev. Oncog.12, 273–287 (2006)
- Ogino S , GoelA: Molecular classification and correlates in colorectal cancer.J. Mol. Diagn.10, 13–27 (2008).
- Karapetis CS , Khambata-FordS, JonkerDJet al. : K-ras mutations and benefit from cetuximab in advanced colorectal cancer.N. Engl. J. Med.359, 1757–1765 (2008).
- Van Cutsem E , KöhneCH, HitreEet al. : Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.N. Engl. J. Med.360, 1408–1417 (2009).
- Di Nicolantonio F , MartiniM, MolinariFet al. : Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.J. Clin. Oncol.26, 5705–5712 (2008).
- Scartozzi M , GaliziaE, ChiorriniSet al. : Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.Ann. Oncol.20, 227–230 (2009).
- Iwanicki-Caron I , Di FioreF, RoqueIet al.: Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer.J. Clin. Oncol.26, 3681–3686 (2008).